Shares of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) have earned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Brokerages have set a twelve-month consensus price target of $10.00 for the company and are anticipating that the company will post ($0.69) EPS for the current quarter, according to Zacks. Zacks has also given Diffusion Pharmaceuticals an industry rank of 53 out of 256 based on the ratings given to related companies.
A number of brokerages have weighed in on DFFN. HC Wainwright reissued a “buy” rating on shares of Advanced Emissions Solutions in a research note on Wednesday, March 20th. ValuEngine lowered Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st.
Shares of Diffusion Pharmaceuticals stock remained flat at $$2.18 during trading hours on Friday. The company’s stock had a trading volume of 230,606 shares, compared to its average volume of 116,902. Diffusion Pharmaceuticals has a one year low of $1.83 and a one year high of $11.00. The business’s 50-day moving average price is $2.97. The company has a current ratio of 5.35, a quick ratio of 5.35 and a debt-to-equity ratio of 0.02.
Diffusion Pharmaceuticals (NASDAQ:DFFN) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. On average, analysts forecast that Diffusion Pharmaceuticals will post -2.27 EPS for the current fiscal year.
A hedge fund recently bought a new stake in Diffusion Pharmaceuticals stock. Two Sigma Investments LP acquired a new position in shares of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 32,176 shares of the company’s stock, valued at approximately $64,000. Two Sigma Investments LP owned about 0.95% of Diffusion Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 6.20% of the company’s stock.
About Diffusion Pharmaceuticals
Diffusion Pharmaceuticals Inc, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke.
Featured Article: Understanding each part of a balance sheet
Get a free copy of the Zacks research report on Diffusion Pharmaceuticals (DFFN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.